1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Relapsed Acute Myeloid Leukemia Drug Revenue
1.4 Market Analysis by Type
1.4.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 aNK Program
1.4.3 AT-9283
1.4.4 BI-836858
1.4.5 binimetinib
1.4.6 BL-8040
1.4.7 Others
1.5 Market by Application
1.5.1 Global Relapsed Acute Myeloid Leukemia Drug Market Share by Application: 2021-2026
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Relapsed Acute Myeloid Leukemia Drug Market
1.8.1 Global Relapsed Acute Myeloid Leukemia Drug Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Relapsed Acute Myeloid Leukemia Drug Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Relapsed Acute Myeloid Leukemia Drug Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Relapsed Acute Myeloid Leukemia Drug Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Region (2015-2020)
3.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Revenue Market Share by Region (2015-2020)
3.3 North America Relapsed Acute Myeloid Leukemia Drug Sales Volume
3.3.1 North America Relapsed Acute Myeloid Leukemia Drug Sales Volume Growth Rate (2015-2020)
3.3.2 North America Relapsed Acute Myeloid Leukemia Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume
3.4.1 East Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Relapsed Acute Myeloid Leukemia Drug Sales Volume (2015-2020)
3.5.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume (2015-2020)
3.6.1 South Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume (2015-2020)
3.7.1 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Relapsed Acute Myeloid Leukemia Drug Sales Volume (2015-2020)
3.8.1 Middle East Relapsed Acute Myeloid Leukemia Drug Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Relapsed Acute Myeloid Leukemia Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Relapsed Acute Myeloid Leukemia Drug Sales Volume (2015-2020)
3.9.1 Africa Relapsed Acute Myeloid Leukemia Drug Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Relapsed Acute Myeloid Leukemia Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Relapsed Acute Myeloid Leukemia Drug Sales Volume (2015-2020)
3.10.1 Oceania Relapsed Acute Myeloid Leukemia Drug Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Relapsed Acute Myeloid Leukemia Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Relapsed Acute Myeloid Leukemia Drug Sales Volume (2015-2020)
3.11.1 South America Relapsed Acute Myeloid Leukemia Drug Sales Volume Growth Rate (2015-2020)
3.11.2 South America Relapsed Acute Myeloid Leukemia Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Relapsed Acute Myeloid Leukemia Drug Sales Volume (2015-2020)
3.12.1 Rest of the World Relapsed Acute Myeloid Leukemia Drug Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Relapsed Acute Myeloid Leukemia Drug Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Relapsed Acute Myeloid Leukemia Drug Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Relapsed Acute Myeloid Leukemia Drug Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Relapsed Acute Myeloid Leukemia Drug Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Relapsed Acute Myeloid Leukemia Drug Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Relapsed Acute Myeloid Leukemia Drug Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Relapsed Acute Myeloid Leukemia Drug Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Relapsed Acute Myeloid Leukemia Drug Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Relapsed Acute Myeloid Leukemia Drug Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Relapsed Acute Myeloid Leukemia Drug Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Volume Market Share by Type (2015-2020)
14.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Revenue Market Share by Type (2015-2020)
14.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Relapsed Acute Myeloid Leukemia Drug Consumption Volume by Application (2015-2020)
15.2 Global Relapsed Acute Myeloid Leukemia Drug Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Relapsed Acute Myeloid Leukemia Drug Business
16.1 4SC AG
16.1.1 4SC AG Company Profile
16.1.2 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Specification
16.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Astellas Pharma Inc.
16.2.1 Astellas Pharma Inc. Company Profile
16.2.2 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.2.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Agios Pharmaceuticals, Inc.
16.3.1 Agios Pharmaceuticals, Inc. Company Profile
16.3.2 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.3.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 AbbVie Inc.
16.4.1 AbbVie Inc. Company Profile
16.4.2 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.4.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 Array BioPharma Inc.
16.5.1 Array BioPharma Inc. Company Profile
16.5.2 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.5.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Actinium Pharmaceuticals, Inc.
16.6.1 Actinium Pharmaceuticals, Inc. Company Profile
16.6.2 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.6.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 AstraZeneca Plc
16.7.1 AstraZeneca Plc Company Profile
16.7.2 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Specification
16.7.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Arog Pharmaceuticals, Inc.
16.8.1 Arog Pharmaceuticals, Inc. Company Profile
16.8.2 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.8.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Amgen Inc.
16.9.1 Amgen Inc. Company Profile
16.9.2 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.9.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Astex Pharmaceuticals, Inc.
16.10.1 Astex Pharmaceuticals, Inc. Company Profile
16.10.2 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.10.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Bristol-Myers Squibb Company
16.11.1 Bristol-Myers Squibb Company Company Profile
16.11.2 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Specification
16.11.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 Cornerstone Pharmaceuticals, Inc.
16.12.1 Cornerstone Pharmaceuticals, Inc. Company Profile
16.12.2 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.12.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.13 AVEO Pharmaceuticals, Inc.
16.13.1 AVEO Pharmaceuticals, Inc. Company Profile
16.13.2 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.13.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.14 Calithera Biosciences, Inc.
16.14.1 Calithera Biosciences, Inc. Company Profile
16.14.2 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.14.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.15 Boston Biomedical, Inc.
16.15.1 Boston Biomedical, Inc. Company Profile
16.15.2 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.15.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.16 BioLineRx, Ltd.
16.16.1 BioLineRx, Ltd. Company Profile
16.16.2 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.16.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.17 CTI BioPharma Corp.
16.17.1 CTI BioPharma Corp. Company Profile
16.17.2 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Specification
16.17.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.18 Celgene Corporation
16.18.1 Celgene Corporation Company Profile
16.18.2 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Specification
16.18.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.19 Boehringer Ingelheim GmbH
16.19.1 Boehringer Ingelheim GmbH Company Profile
16.19.2 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Specification
16.19.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Relapsed Acute Myeloid Leukemia Drug Manufacturing Cost Analysis
17.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug
17.4 Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Relapsed Acute Myeloid Leukemia Drug Distributors List
18.3 Relapsed Acute Myeloid Leukemia Drug Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Relapsed Acute Myeloid Leukemia Drug (2021-2026)
20.2 Global Forecasted Revenue of Relapsed Acute Myeloid Leukemia Drug (2021-2026)
20.3 Global Forecasted Price of Relapsed Acute Myeloid Leukemia Drug (2015-2026)
20.4 Global Forecasted Production of Relapsed Acute Myeloid Leukemia Drug by Region (2021-2026)
20.4.1 North America Relapsed Acute Myeloid Leukemia Drug Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Relapsed Acute Myeloid Leukemia Drug Production, Revenue Forecast (2021-2026)
20.4.3 Europe Relapsed Acute Myeloid Leukemia Drug Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Relapsed Acute Myeloid Leukemia Drug Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Relapsed Acute Myeloid Leukemia Drug Production, Revenue Forecast (2021-2026)
20.4.7 Africa Relapsed Acute Myeloid Leukemia Drug Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Relapsed Acute Myeloid Leukemia Drug Production, Revenue Forecast (2021-2026)
20.4.9 South America Relapsed Acute Myeloid Leukemia Drug Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Relapsed Acute Myeloid Leukemia Drug Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Relapsed Acute Myeloid Leukemia Drug by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Relapsed Acute Myeloid Leukemia Drug by Country
21.2 East Asia Market Forecasted Consumption of Relapsed Acute Myeloid Leukemia Drug by Country
21.3 Europe Market Forecasted Consumption of Relapsed Acute Myeloid Leukemia Drug by Countriy
21.4 South Asia Forecasted Consumption of Relapsed Acute Myeloid Leukemia Drug by Country
21.5 Southeast Asia Forecasted Consumption of Relapsed Acute Myeloid Leukemia Drug by Country
21.6 Middle East Forecasted Consumption of Relapsed Acute Myeloid Leukemia Drug by Country
21.7 Africa Forecasted Consumption of Relapsed Acute Myeloid Leukemia Drug by Country
21.8 Oceania Forecasted Consumption of Relapsed Acute Myeloid Leukemia Drug by Country
21.9 South America Forecasted Consumption of Relapsed Acute Myeloid Leukemia Drug by Country
21.10 Rest of the world Forecasted Consumption of Relapsed Acute Myeloid Leukemia Drug by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer